Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer


Breast cancer is one of the most common cancers in humans and will on average affect up to one in eight women in their lifetime in the United States and Europe1. The Women’s Health Initiative and the Million Women Study have shown that hormone replacement therapy is associated with an increased risk of incident and fatal breast cancer2,3. In particular, synthetic progesterone derivatives (progestins) such as medroxyprogesterone acetate (MPA), used in millions of women for hormone replacement therapy and contraceptives, markedly increase the risk of developing breast cancer. Here we show that the in vivo administration of MPA triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-κB ligand) in mammary-gland epithelial cells. Genetic inactivation of the RANKL receptor RANK in mammary-gland epithelial cells prevents MPA-induced epithelial proliferation, impairs expansion of the CD49fhi stem-cell-enriched population, and sensitizes these cells to DNA-damage-induced cell death. Deletion of RANK from the mammary epithelium results in a markedly decreased incidence and delayed onset of MPA-driven mammary cancer. These data show that the RANKL/RANK system controls the incidence and onset of progestin-driven breast cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: The progesterone derivative MPA triggers in vivo RANKL expression and the proliferation of mammary epithelial cells through RANK.
Figure 2: RANK controls the incidence and onset of progestin-driven mammary cancer.
Figure 3: RANK induces NF-κB signalling and anchorage-independent growth.
Figure 4: RANK protects from radiation-induced epithelial apoptosis and controls mammosphere formation.


  1. 1

    Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009)

    Article  Google Scholar 

  2. 2

    Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288, 321–333 (2002)

    CAS  Article  Google Scholar 

  3. 3

    Beral, V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419–427 (2003)

    CAS  Article  Google Scholar 

  4. 4

    Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999)

    ADS  CAS  Article  Google Scholar 

  5. 5

    Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412–2424 (1999)

    CAS  Article  Google Scholar 

  6. 6

    Rossi, S. W. et al. RANK signals from CD4+3 inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204, 1267–1272 (2007)

    CAS  Article  Google Scholar 

  7. 7

    Hanada, R. et al. Central control of fever and female body temperature by RANKL/RANK. Nature 462, 505–509 (2009)

    ADS  CAS  Article  Google Scholar 

  8. 8

    Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41–50 (2000)

    CAS  Article  Google Scholar 

  9. 9

    Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006)

    ADS  CAS  Article  Google Scholar 

  10. 10

    Morony, S. et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61, 4432–4436 (2001)

    CAS  PubMed  Google Scholar 

  11. 11

    Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009)

    CAS  Article  Google Scholar 

  12. 12

    Beleut, M. et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA 107, 2989–2994 (2010)

    ADS  CAS  Article  Google Scholar 

  13. 13

    Pike, M. C. et al. Estrogen–progestin replacement therapy and endometrial cancer. J. Natl. Cancer Inst. 89, 1110–1116 (1997)

    CAS  Article  Google Scholar 

  14. 14

    el-Mahgoub, S., Karim, M. & Ammar, R. Long-term use of depot medroxy progesterone acetate as a contraceptive. Acta Obstet. Gynecol. Scand. 51, 251–255 (1972)

    CAS  Article  Google Scholar 

  15. 15

    Hofseth, L. J. et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84, 4559–4565 (1999)

    CAS  PubMed  Google Scholar 

  16. 16

    Wada, T., Nakashima, T., Hiroshi, N. & Penninger, J. M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17–25 (2006)

    CAS  Article  Google Scholar 

  17. 17

    Srivastava, S. et al. Receptor activator of NF-κB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J. Biol. Chem. 278, 46171–46178 (2003)

    CAS  Article  Google Scholar 

  18. 18

    Aldaz, C. M., Liao, Q. Y., LaBate, M. & Johnston, D. A. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17, 2069–2072 (1996)

    CAS  Article  Google Scholar 

  19. 19

    Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798–802 (2010)

    ADS  CAS  Article  Google Scholar 

  20. 20

    Joshi, P. A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803–807 (2010)

    ADS  CAS  Article  Google Scholar 

  21. 21

    Cao, Y. et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763–775 (2001)

    CAS  Article  Google Scholar 

  22. 22

    Wright, A. et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 13, 705–716 (2007)

    CAS  Article  Google Scholar 

  23. 23

    Kim, N. S. et al. Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell. Biol. 26, 1002–1013 (2006)

    CAS  Article  Google Scholar 

  24. 24

    Freedman, V. H. & Shin, S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3, 355–359 (1974)

    CAS  Article  Google Scholar 

  25. 25

    Lee, J. et al. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 107, 2686–2693 (2006)

    CAS  Article  Google Scholar 

  26. 26

    Ewan, K. B. et al. Transforming growth factor-β1 mediates cellular response to DNA damage in situ. Cancer Res. 62, 5627–5631 (2002)

    CAS  PubMed  Google Scholar 

  27. 27

    Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62–73 (2010)

    CAS  Article  Google Scholar 

  28. 28

    Cao, Y., Luo, J. L. & Karin, M. IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc. Natl Acad. Sci. USA 104, 15852–15857 (2007)

    ADS  CAS  Article  Google Scholar 

  29. 29

    Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    CAS  Article  Google Scholar 

  30. 30

    McTiernan, A. et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women’s Health Initiative randomized trial. J. Natl. Cancer Inst. 97, 1366–1376 (2005)

    CAS  Article  Google Scholar 

  31. 31

    Wagner, K. U. et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res. 10, 545–553 (2001)

    CAS  Article  Google Scholar 

  32. 32

    Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589–596 (1998)

    CAS  Article  Google Scholar 

  33. 33

    Kuhn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427–1429 (1995)

    ADS  CAS  Article  Google Scholar 

  34. 34

    Tarutani, M. et al. Tissue-specific knockout of the mouse Pig-a gene reveals important roles for GPI-anchored proteins in skin development. Proc. Natl Acad. Sci. USA 94, 7400–7405 (1997)

    ADS  CAS  Article  Google Scholar 

  35. 35

    Gareus, R. et al. Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nature Cell Biol. 9, 461–469 (2007)

    CAS  Article  Google Scholar 

  36. 36

    Aliprantis, A. O. et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Invest. 118, 3775–3789 (2008)

    CAS  Article  Google Scholar 

  37. 37

    Stingl, J. et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993–997 (2006)

    ADS  CAS  Article  Google Scholar 

  38. 38

    Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84–88 (2006)

    ADS  CAS  Article  Google Scholar 

  39. 39

    Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003)

    CAS  Article  Google Scholar 

  40. 40

    Robinson, G. W. & Hennighausen, L. Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions. Development 124, 2701–2708 (1997)

    CAS  PubMed  Google Scholar 

  41. 41

    Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176 (1998)

    CAS  Article  Google Scholar 

Download references


We thank all members of our laboratories for helpful discussions; G. Forni for providing NeuT transgenic mice. A.O.A. is a recipient of a Career Award for Medical Scientists from the Burroughs Wellcome Fund. L.G. is supported by National Institutes of Health (NIH) grant HD055601. G.S’s work is supported by the German Research Council (Deutsche Forschungsgemeinschaft (DFG): FOR643, SFB641 and SPP1468), by the Interdisciplinary Center for Clinical Sciences Erlangen and by the focus programme SPP1468 (Immunobone) of the DFG and the Masterswitch project of the European Union (EU). C.J.O. is supported by the National Health and Medical Research Council of Australia, the Australian Cancer Research Fund and the Cancer Institute New South Wales. D.S. is supported by the EU InflaCare network. M.W. is supported by a grant from the University College London (UCL) Hospital/UCL Comprehensive Biomedical Research Centre project no. 152, and part of this work was undertaken at UCL Hospital/UCL, which received a proportion of its funding from the Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. J.M.P. is supported by grants from Institute of Molecular Biotechnology, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, GEN-AU (AustroMouse), an EU Marie Curie Excellence Grant, and a European Research Council Advanced Grant. Special thanks go to Limin Zhang, who provided a first idea for this manuscript and died much too early of breast cancer.

Author information




D.S. performed most experiments together with A.L. (NeuT experiments) and V.S. (experiments with MPA and DMBA). A.L. generated the RANKfloxed mice. L.K. analysed the tumour section as an expert pathologist. R.H. helped with hormone treatment of mice. P.A.J. and R.K. helped with FACS analysis of mammary-stem-cell populations. A.P. helped in gene set enrichments. H.L. and C.J.O. performed the experiments on prolactin receptor mutant mice. L.G., with A.A. and M.P., provided essential mouse strains and input to the paper. G.S. and M.W. helped in human experiments and read the manuscript critically. J.M.P. coordinated the project, wrote the manuscript, and together with D.S. designed the experiments.

Corresponding author

Correspondence to Josef M. Penninger.

Ethics declarations

Competing interests

J.M.P. declares that IMBA, his host institute, is planning to submit a patent on blocking RANKL/RANK for future treatment/prevention of breast cancer, and that J.M.P. owns shares in Amgen, a company that developed RANKL blocking antibodies. No other competing financial interest is known.

Supplementary information

Supplementary Information

This file contains Supplementary Text containing information on Rank detection in tumors and Cre effects and Gene expression profiling. The file also contains Supplementary Figures 1-16 with legends and additional references. (PDF 3481 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schramek, D., Leibbrandt, A., Sigl, V. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98–102 (2010). https://doi.org/10.1038/nature09387

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing